Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Sage Therapeutics (NASDAQ:SAGE) Issues Quarterly Earnings Results - MarketBeat
Wedbush Reiterates "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Short Interest in Sage Therapeutics, Inc. (NASDAQ:SAGE) Decreases By 32.0% - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 32.0% in January - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Q1 Earnings Forecast for SAGE Issued By Leerink Partnrs - MarketBeat
Scotiabank Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $12.00 - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
Sage Therapeutics' (SAGE) Hold Rating Reiterated at Needham & Company LLC - MarketBeat
Pages
1
2
3
4
5
6
7
8
9
next ›
last »
×